Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Longeveron Inc. - LGVN
06:03pm, Tuesday, 17'th Aug 2021
New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN). Such investors
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Longeveron Inc. - LGVN
05:03pm, Monday, 16'th Aug 2021
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN). Such investors are advised
Longeveron's (LGVN) CEO Geoff Green on Q2 2021 Results - Earnings Call Transcript
05:45pm, Saturday, 14'th Aug 2021
Longeveron's (LGVN) CEO Geoff Green on Q2 2021 Results - Earnings Call Transcript
Longeveron Shares Increase Over 10% Pre-Market: Why It Happened
07:41am, Friday, 13'th Aug 2021
The shares of Longeveron Inc. (NASDAQ: LGVN) increased by over 10% pre-market. This is why it happened.
Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not Met
07:08am, Friday, 13'th Aug 2021
Florida-based biopharma Longeveron Inc. (NASDAQ: LGVN), which is engaged in the development of cell therapies for chronic age-related and life-threatening conditions, announced Friday results for a m
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
07:00am, Friday, 13'th Aug 2021
-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180
Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021
08:30am, Tuesday, 10'th Aug 2021
MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS
03:02pm, Thursday, 29'th Jul 2021
Photo by Anna Shvets from Pexels Now more than ever, regenerative medicine companies like Mesoblast (NASDAQ: MESO), Celularity (NASDAQ: CELU), Athersys (NASDAQ: ATHX), and Pluristem Therapeutics (NASD
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval
03:38pm, Wednesday, 07'th Jul 2021
Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based therapy) after promising res
Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting
08:00am, Wednesday, 30'th Jun 2021
MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related an
Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company's corporate outlook, Green participated in a panel entitled
- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer's Disease - Miami, Florida – June 24 th , 2021 - Longeveron Inc. (NASDAQ: LGVN)
- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer's Disease - Miami, Florida – June 24 th , 2021 - Longeveron Inc. (NASDAQ: LGVN)
Longeveron's (LGVN) CEO Geoff Green on Q1 2021 Results - Earnings Call Transcript
01:20pm, Friday, 14'th May 2021
Longeveron's (LGVN) CEO Geoff Green on Q1 2021 Results - Earnings Call Transcript
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
08:00am, Friday, 14'th May 2021
MIAMI, May 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l
